Oct 24, 2023Former U.S. Commissioner of FDA Stephen M. Hahn, M.D. Appointed to Alpha Tau Advisory BoardJERUSALEM, October 24, 2023 -- Alpha Tau Medical Ltd. ("Alpha Tau", or the “Company”) (NASDAQ: DRTS, DRTSW), the developer of the...
Sep 14, 2023Alpha Tau Treats First Patient with Advanced Inoperable Pancreatic Cancer at Hadassah Medical CenterJERUSALEM, Sept. 14, 2023 -- Alpha Tau Medical Ltd. ("Alpha Tau", or the “Company”) (NASDAQ: DRTS, DRTSW), the developer of the...
Aug 29, 2023Alpha Tau Medical Announces Second Quarter 2023 Financial Results and Provides Corporate Update– Treated the first patient with advanced inoperable pancreatic cancer in a safety and feasibility trial in Canada in April – – 89% CR,...
Aug 24, 2023Alpha Tau Medical to Participate in September Investor ConferencesJERUSALEM, August 24, 2023 -- Alpha Tau Medical Ltd. ("Alpha Tau", or the “Company”) (NASDAQ: DRTS, DRTSW), the developer of the...
Aug 21, 2023Alpha Tau Announces Robust Long-Term Safety and Efficacy Data from Multiple Clinical Trials of Alpha- 81 lesions treated across four feasibility trials of head and neck or skin cancers demonstrated 89% complete response rate. - Two-year...